



Nasdaq: ICU
www.seastarmedical.com

Recent Stock Price (07/20/23)	\$0.52
Market Capitalization	\$7.0M
Common Shares Outstanding	13.5M
Avg. Daily Trading Volume	707,000

Innovative Solutions for the Consequences of Hyperinflammation

SeaStar Medical is developing and commercializing proprietary extracorporeal therapies that target the effector cells that drive systemic inflammation and damage vital organs. SeaStar Medical's novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients in multiple underserved indications.

Targeting FDA approval of the Selective Cytopheretic Device (SCD) for pediatric acute kidney injury (AKI) by 2023 year end under the humanitarian device exemption (HDE) process,

Enrolling patients in the NEUTRALIZE-AKI (NEUTrophil and monocyte deActivation via SeLective Cytopheretic Device – a randomiZed clinical trial in Acute Kidney Injury) with interim results expected in 4Q23

Investment Highlights



Selective Cytopheretic Device (SCD) quells the hyperinflammatory process and cytokine storm by targeting and neutralizing activated effector cells

- SCD addresses hyperinflammation in multiple acute and chronic indications, all high-value and large markets
- SCD's unique method of mechanism of action provides cell-directed extracorporeal therapy at the patient point of care under an FDA medical device regulatory pathway
- Initial work in pediatric and adult AKI generated clinical results demonstrating vastly reduced mortality and the elimination of dependency on hemodialysis
- Multiple near-term regulatory and clinical milestones provide potential to create significant value for shareholders
- Seasoned leadership team with highly relevant business experience and a proven track record of execution

Hyperinflammation is a Serious Condition that Can Lead to Permanent Organ Damage and Death

Hyperinflammation develops when the immune system responds too aggressively to injury, subsequently creating a cytokine storm

Key Drivers of Hyperinflammation: bacterial and viral infections, trauma and surgery can lead to pulmonary infiltrates, lung injury, acute respiratory distress syndrome (ARDS), cardiovascular shock, disseminated intravascular coagulant or renal failure

Hyperinflammation can Result in End-Organ Damage and Failure, with the Potential for Permanent Organ Damage or Death

Current Treatment Options Have Limited Efficacy



IV Fluids



Drugs to Reduce Fever



Ventilation



Dialysis




Blood Transfusion

Therapeutic approaches intended to block soluble mediator targets – such as cytokines or free radicals – have not been proven to be efficacious

There is an urgent need to address hyperinflammation at its source

SCD: Innovative Cell-directed Extracorporeal Therapy Works to Restore Immune System Homeostasis



*SCD is currently under investigation and has not been approved. There is no guarantee that the product will receive authority approval and become commercially available for the uses being investigated.

SCD is not a filter; it creates a microenvironment to neutralize hyperactive neutrophils and transform monocytes

The FDA granted Breakthrough Device designation to SCD for adult AKI in Q2 2022

Significantly Reduced Mortality and Elimination of Dialysis Dependency Demonstrated Across Multiple AKI Clinical Studies

Non-COVID AKI Studies	Patients Treated	Mortality Rate (60 Days)			Dialysis Dependency (60 Days)	
		Mortality Reduction	SCD	Control	SCD	Control
OUS Study	9	56%	22%	78% ¹	0%	25%
U.S. Adult Pilot 002	35	19%	31%	50% ³	0%	25%
U.S. Adult ARF 003	19/27 ²	25%	16%	41%	0%	25%
U.S. Peds SCD 001	16	25%	25%	50% ³	0%	15%-25%

Note: All subjects in these studies were patients with AKI

1. Case-matched controls based on SOFA Scores and age

2. Treated per protocol (iCa in therapeutic range using citrate)

3. Historical control based on published studies ARF = Acute Renal Failure

Positive Results in Pivotal Pediatric AKI Study

Open-label, multicenter pilot study assessed the safety and feasibility of SCD in 16 pediatric patients with AKI and multi-organ dysfunction requiring continuous kidney replacement therapy

Primary Endpoints: Treatment-related adverse events occurring during treatment and Day 60 post-treatment initiation

Results:

- ✓ No SCD-related adverse events
- ✓ 94% of patients survived SCD therapy
- ✓ 75% of patients survived to ICU discharge
- ✓ 100% of ICU survivors were dialysis independent and had normal kidney function at Day 60

Platform Therapy Addressing Multiple High-Value Indications

Indication	Feasibility	Pivotal	Approved
Pediatric Acute Kidney Injury on CKRT	HDE accepted for Review by FDA in July 2022		Potential FDA approval targeted Q1 2023, ~4,000 U.S. patients
Adult Acute Kidney Injury on CKRT	Pivotal Trial Ready		Pivotal trial to commence Q1 2023, ~210,000 U.S. patients
Cardiorenal Syndrome in Congestive Heart Failure (no LVAD)			
Cardiorenal Syndrome in Congestive Heart Failure (LVAD)			
Myocardial Stunning in End-Stage Renal Disease			
Hepatorenal Syndrome			



Exploratory clinical research underway to refine patient populations where SCD may be effective

Expansion opportunities beyond AKI include:

- Acute Respiratory Distress Syndrome (TAM: 200,000)
- Hepato-Renal Syndrome (TAM: 700,000)
- Cardio Renal Syndrome (TAM: 400,000)

What Types of Patients Have Been Treated with the SCD?

3 Organ Failure

On average



50%-60% Sepsis

Among patients

Comorbidities include (but not limited to) morbidly obese and COVID-19 positive – all patients were in the ICU

Pediatric AKI Commercial Overview

Market:

220 Children's Hospitals: ~4,000 AKI pediatric patients; ~7,200 ICU beds

Top 50 Children's Hospitals: ~2,200 AKI pediatric patients; ~4,030 ICU beds

Commercial Preparations:

Product manufacturer



Pediatric SCD license & distribution partner



Key Upcoming Value-Creating Milestones

YE 2023
FDA Approval

YE 2023
Commercial Launch

Adult Acute Kidney Injury

✓ **Q2 2023**
Commenced Pivotal Trial

Q4 2023
Pivotal Study Interim Results

Q3 2024
Pivotal Study Topline Results

Q3 2024
PMA Submission

H1 2025
PMA Approval

H2 2025
Commercial Launch

- Merger into SPAC (Nasdaq: LMAO) on October 28, 2022
- At merger closing entered into forward purchase agreements of shares and warrants with the potential to generate up to \$10 million in proceeds
- \$100 million equity line of credit
- Closed \$3.3 million first tranche in March and \$1.75 million second tranche in May of a \$9.8 million private placement

Investor Contact

LHA Investor Relations

Jody Cain

jcain@lhai.com / 310-691-7100

The information contained herein was obtained from the management SeaStar Medical and other sources LHA believes to be reliable. LHA is engaged by SeaStar Medical as its investor relations agency. This document contains forward-looking statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. Statements in this document, which are not a plain recitation of fact should be considered forward-looking statements. This document shall not constitute an offer to sell, or the solicitation of an offer, to buy or sell securities. Risks relating to SeaStar Medical and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this document, are detailed in SeaStar Medical's latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading "Risk Factors." The forward-looking statements in this document speak only as of this date, and SeaStar Medical disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

July 2023